Hiroto Kikuchi
Hiroto Kikuchi
Publications
HideCombination CXCR4 and PD1 blockade enhances intratumoral dendritic cell activation and immune responses against hepatocellular carcinoma.
Cancer Immunol Res. 2024;13(2):162-170 - PMID: 39514263 - PMCID: PMC11788650 - DOI: 10.1158/2326-6066.CIR-24-0324
Preventing NK cell activation in the damaged liver induced by cabozantinib/PD-1 blockade increases survival in hepatocellular carcinoma models.
Increased CD8+ T-Cell Infiltration and Efficacy for Multikinase Inhibitors after PD-1 Blockade in Hepatocellular Carcinoma.
J Natl Cancer Inst. 2022;114(9):1301-1305 - PMID: 35288743 - PMCID: PMC9468280 - DOI: 10.1093/jnci/djac051
A nonrandomized phase I and biomarker trial of regorafenib in advanced myeloid malignancies.
Placental growth factor promotes tumour desmoplasia and treatment resistance in intrahepatic cholangiocarcinoma.
NASH limits anti-tumour surveillance in immunotherapy-treated HCC.
Nature. 2021;592(7854):450-456 - PMID: 33762733 - PMCID: PMC8046670 - DOI: 10.1038/s41586-021-03362-0
Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma.
J Immunother Cancer. 2020;8(2):ePub - PMID: 33234602 - PMCID: PMC7689089 - DOI: 10.1136/jitc-2020-001435